MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide

    C. Pauletti, N. Locuratolo, D. Mannarelli, A. Maffucci, A. Petritis, F. Fattapposta (Rome, Italy)

    Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…
  • 2022 International Congress

    Transcranial alternating current stimulation modulates motor network connectivity in patients with blepharospasm

    K. Popli, H. Nawaz, M. Barrett, M. Palenzuela, D. Peterson, B. Berman (Richmond, USA)

    Objective: To determine if inhibitory transcranial alternating current stimulation (tACS) applied to the sensorimotor cortex can modulate regional and global neural activity in patients with…
  • 2022 International Congress

    Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study

    S. Joza, M. Hu, KY. Jung, D. Kunz, P. Dusek, D. Arnaldi, B. Högl, L. Ferini-Strambi, M. Terzaghi, F. Sixel-Döring, M. Puligheddu, F. Provini, S. Lewis, J. Liu, J. Bušková, A. Nicoletti, Y. Dauvilliers, C. Bassetti, M. Lawton, HJ. Kim, JS. Sunwoo, F. Bes, K. Sonka, P. Mattioli, A. Stefani, A. Ibrahim, G. Fiamingo, B. Mollenhauer, C. Trenkwalder, M. Figorilli, P. Cortelli, L. Baldelli, K. Ehgoetz Martens, Y. Li, E. Cicero, L. Guiraud, C. Schaefer, A. Pelletier, R. Postuma (Montreal, Canada)

    Objective: To inform the design of randomized neuroprotective trials in prodromal Parkinson’s disease (PD) by assessing the progression of prodromal markers in idiopathic rapid eye…
  • 2022 International Congress

    Association between dihydropyridines and dementia conversion in Parkinson’s disease

    JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

    Objective: To investigate the role of antihypertensive drugs, including dihydropyridines, on nigrostriatal dopamine and dementia conversion in Parkinson's disease Background: Several experimental and clinical studies…
  • 2022 International Congress

    Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief in a large cohort of incoA-treated pts with spasticity-associated pain (SAP) using pooled data from mostly placebo-controlled phase 2/3 studies.…
  • 2022 International Congress

    [18F]FDG PET in hyperkinetic movement disorders: a systematic review

    E. Timmers, M. Klamer, R. Marapin, A. Lammertsma, B. de Jong, R. Dierckx, M. Tijssen (Groningen, Netherlands)

    Objective: To give a comprehensive literature overview of alterations in regional cerebral glucose metabolism, measured using [18F]FDG PET, in hyperkinetic movement disorders. In addition, correlations…
  • 2022 International Congress

    Muscarinic M2 cholinergic receptors in cervical dystonia

    P. Kassavetis, M. Hosseini, K. Mente, R. Waugh, E. Shamim, W. Dieckmann, P. Herscovitch, M. Hallett, S. Horovitz (Salt Lake City, USA)

    Objective: To characterize the M2 muscarinic acetylcholine receptor binding in patients with cervical dystonia, measured with non-invasive high-resolution PET, using [18F]FP-TZTP ligand. Background: While antimuscarinic…
  • 2022 International Congress

    Myoclonus in a Large Urban Center: 10 Year Experience

    K. Oh, M. Hamed, H. Sarva, D. Victor (New York, USA)

    Objective: To describe various forms of myoclonus in admitted patients in a 10-year period. Background: Myoclonus consists of brief, shock-like involuntary movements. It may occur…
  • 2022 International Congress

    Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.

    R. Mehanna, K. Smilowska, A. Merola, B. Zhang, B. Post, C. Marras, J. Fleisher, K. Kumar, M. Salari, O. Ross, R. Alcalay, T. Hatano, V. Mcconvey, Y-R. Wu, E-K. Tan, R. Savica (Houston, USA)

    Objective: To define the nomenclature for Early Onset Parkinson Disease (EOPD) / Young Onset Parkinson Disease (YOPD), and the age at onset (AAO) cut off…
  • 2022 International Congress

    To be or not to bupropion: a drug-induced parkinsonism?

    A. Silva, J. Pinto, M. Gago, M. Rodrigues (Braga, Portugal)

    Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…
  • « Previous Page
  • 1
  • …
  • 105
  • 106
  • 107
  • 108
  • 109
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley